AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 281 min read$ORIC

Piscitelli Dominic sold $1.1M of ORIC

Piscitelli Dominic (Chief Financial Officer) sold 77,000 shares of Oric Pharmaceuticals, Inc. (ORIC) at $13.69 ($1.05M total) on 2026-08-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Piscitelli Dominic
Published Aug 28, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ORIC
Bearish
medium confidence
Mentioned
$ORIC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ORICBearishLow
01

Why it matters

The disclosed sale reduces insider ownership, which may be interpreted as a negative signal, but the size is modest.

02

Market read

Primary relevance is to ORIC shareholders; limited broader market impact.

03

What to watch

Potential upcoming clinical data releases or financing events that could offset the sell‑off.

Relevance 5/10Novelty 4/10Timing: filed today (2026‑08‑28)

Background

Form 4 filing discloses insider transactions; CFO sales are monitored for potential signals.

Company-level read

Ticker impact

$ORICBearishMedium confidence
Context

CFO Piscitelli Dominic sold 77,000 shares for $1.05M via a 10b5‑1 plan, reducing his stake to 69,828 shares.

Expected impact

Modest downward pressure over the next few days.

Evidence & confidence

CFO insider sales are material but the amount is modest relative to market cap; market may react lightly.

Market effects

Sector

Minimal impact on the broader biotech sector; insider sales are common and not sector‑wide.

Regional

No significant regional effect; limited to Oric shareholders.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move unrelated to company fundamentals, so price may remain stable.

Key entities

  • Company
    Oric Pharmaceuticals, Inc.

    US‑listed biotech company (ticker ORIC).

  • Executive
    Piscitelli Dominic

    Chief Financial Officer of Oric.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ORIC insider trading history →

Related articles

AUG 3
$ORICMed

Oric Pharmaceuticals, Inc. (ORIC): Results of Operations and Financial Condition

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ORIC ® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Ba

SEC EDGAR 8-K6 min
SEP 11
$DELLLow

Silver Lake Partners V DE (AIV), L.P. (Durban Egon) sold $14.9M of DELL (indirect holdings)

Silver Lake Partners V DE (AIV), L.P. sold 27,629 indirectly-held shares of Dell Technologies Inc. (DELL) at an average of $540.39 ($534.09–$550.71, $14.93M total) across 17 trades on 2026-09-09. Filed jointly with Silver Lake Technology Associates V, L.P. (Director), SLTA V (GP), L.L.C. (Director), Silver Lake Group, L.L.C. (Director) and Durban Egon (Director).

SEC EDGAR1 min
SEP 11
$DELLMed

Silver Lake Partners IV, L.P. (Durban Egon) sold $28.5M of DELL (indirect holdings)

Silver Lake Partners IV, L.P. sold 52,708 indirectly-held shares of Dell Technologies Inc. (DELL) at an average of $540.39 ($534.09–$550.71, $28.48M total) across 17 trades on 2026-09-09. Filed jointly with Silver Lake Technology Associates IV, L.P. (Director), SLTA IV (GP), L.L.C. (Director), Silver Lake Group, L.L.C. (Director) and Durban Egon (Director).

SEC EDGAR1 min